Novartis AG, Google Inc. Strike Smart Contact Lenses Pact
Novartis to license Google "smart lens" technology Innovative technology offers potential to transform eye care and further enhance Alcon's leadership
Source : devicespace.com
|
|
 Twitter
Copy link
Link copied!
|
Novartis et Google accordent leur vue sur les lentilles intelligentes - La Tribune.fr
Le géant pharmaceutique suisse a annoncé ce mardi 15 juillet avoir trouvé un accord sur la technologie des lentilles intelligentes... Initiée par le géant du web, la technologie des lentilles intelligentes a une visée médicale. Elle doit notamment aider les personnes atteintes de diabète à gérer leur maladie : une diode électroluminescente miniature intégrée à la lentille avertira le porteur chaque fois que son taux de sucre s'approchera d'un niveau à risque. Un projet en gestation depuis plusieurs mois Ce projet, Google en parle depuis plusieurs mois. En janvier dernier, la firme de Mountain View avait annoncé sur son blog "rechercher des partenaires qui ont une expertise dans ce type de produits".
Source : latribune.fr
|
|
Twitter
Copy link
Link copied!
|
British wound care company starting clinical trials to bring tests to U.S.
British diagnostics company Woundchek Laboratories will start U.S. clinical trials; it hopes for FDA clearance so it can market wound care tests in the U.S.
Source : medcitynews.com
|
|
Twitter
Copy link
Link copied!
|
Ce changement de nom s’inscrit dans la stratégie d’Acobiom d’affirmer son positionnement dans la médecine personnalisée, et son ambition dans la découverte de biomarqueurs et le développement de diagnostics compagnons.
Skuldtech, société créée en 1999 et experte dans la découverte de biomarqueurs génomiques et transcriptomiques, s’est spécialisée dans le développement de diagnostics innovants. Elle prend aujourd’hui le nom d’Acobiom. Ce nouveau nom vise à confirmer le virage stratégique amorcé par la société en 2009 vers la médecine personnalisée (ou médecine de précision), l’un des enjeux majeurs de la médecine de demain.
|
|
Twitter
Copy link
Link copied!
|
Ce nouvel outil éducationnel exhaustif marque pour Sebia dix années d’excellence dans le domaine de la séparation des hémoglobines par électrophorèse capillaire... Sebia, leader mondial dans l’électrophorèse des protéines et premier fournisseur de tests dans le diagnostic des désordres de l’hémoglobine, annonce aujourd’hui le lancement de son Atlas des Hémoglobines. Cet outil innovant permettra aux utilisateurs de l’électrophorèse capillaire Sebia d’orienter leur diagnostic d’hémoglobinopathies.
|
|
Twitter
Copy link
Link copied!
|
The growth in personalized medicine has led to increased interest in companion diagnostics (CDx) tests or tests that match the right therapy to the patient...A new analysis from Frost & Sullivan (London, United Kingdom) finds that the CDx market earned revenues of USD 457 million in 2013 and estimates this to reach USD 1,295.1 million in 2018, at a compound annual growth rate of 23.2 %. .. Limited regulatory barriers for drug and diagnostic combination products, which the current in vitro diagnostic directive classifies under the low-risk category, are easing market access. As nearly all diagnostic tests in Europe belong to the low risk category, they are exempt from pre-market evaluation. As a result, manufacturers tend to self-assess conformity, self-certify CDx products, and CE mark them before sale in the European market. This laid-back process has resulted in a higher rate of approval of new CDx tests and products.”
|
|
Twitter
Copy link
Link copied!
|
Illumina Inks NIPT Deals Covering Parts of Europe | GenomeWeb Daily News | Sequencing | GenomeWeb
Illumina today announced agreements with three organizations for use of its next-generation sequencing technologies to develop and run non-invasive prenatal testing in parts of Europe. Illumina's deals are with Biomnis, which plans to make NIPT available in France; with Genoma for NIPT services in Italy; and with the Center for Human Genetics and Laboratory Diagnostics, which will offer NIPT in Germany. Under the terms of the agreement, Biomnis, Genoma, and the Center for Human Genetics and Laboratory Diagnostics will use Illumina's HiSeq 2500 platform and consumables to develop their tests.
Source : genomeweb.com
|
|
Twitter
Copy link
Link copied!
|
Roche Invests in Sequencing Startup Stratos Genomics; Will Help Develop Nanopore Technology | GenomeWeb Daily News | Sequencing | GenomeWeb
Roche said today that it has made a strategic investment in nanopore sequencing startup Stratos Genomics and is collaborating to further develop the firm's sequencing chemistry.
Source : genomeweb.com
|
|
Twitter
Copy link
Link copied!
|
Alere Inc. Wins FDA Approval For Alere(TM) i Influenza A And B Test
Alere Receives FDA Clearance for Alere™ i Influenza A and B Test First-ever Platform to Deliver Highly Accurate, Molecular Results in Under 15 Minutes
Source : devicespace.com
|
|
Twitter
Copy link
Link copied!
|
Cepheid Partners with AstraZeneca, GSK, Cubist to Develop Rapid Dx for Drug-Resistant Pathogens | GenomeWeb Daily News | Clinical Genomics | GenomeWeb
Cepheid is collaborating with AstraZeneca, Cubist Pharmaceuticals, and GlaxoSmithKline to develop a rapid diagnostic test that can analyze multi-drug resistant pathogens and help doctors prescribe the most beneficial antibiotics for patients. Cepheid is currently developing the Xpert Carba-R test for assessing bacteria from rectal swab samples. The goal of the consortium is to enable the test to also analyze a variety of other biological samples, such as respiratory samples from pneumonia patients.
Source : genomeweb.com
|
|
Twitter
Copy link
Link copied!
|
IntegraGen se prépare à révolutionner le diagnostic des cancers
Imaginer un outil logiciel qui permette aux cliniciens en cancérologie d'affiner leur diagnostic et de personnaliser le traitement de chaque patient, en fonction du profil génétique d'une tumeur. C'est le défi ambitieux du projet ICE (Interpretation of Clinica Exome) que lance aujourd'hui IntegraGen, le spécialiste français des tests de diagnostic moléculaire pour l'oncologie et l'autisme.
Source : lesechos.fr
|
|
Twitter
LinkedIn
Copy link
Link copied!
|
Sequenom has sold its Bioscience business for up-to-USD 35.8 million to Agena Bioscience, which said it plans to expand clinical...
|
|
Twitter
Copy link
Link copied!
|
Canada Approves Roche's HPV Test as a First-line Cervical Cancer Screen | GenomeWeb Daily News | PCR/Sample Prep | GenomeWeb
Roche announced on Tuesday that Health Canada approved the cobas 4800 HPV Test as a first-line primary screening test for cervical cancer in women at least 25 years old.
Source : genomeweb.com
|
|
Twitter
Copy link
Link copied!
|
|
Bientôt des lentilles connectées pour les diabétiques
Fini le calvaire de la piqûre au bout du doigt ? Google et Novartis planchent sur des dispositifs oculaires révolutionnaires mesurant la glycémie.
Source : lepoint.fr
|
|
Twitter
Copy link
Link copied!
|
Superbugs and the role of diagnostics explained | MedTech Views
The discussion over superbugs moved center stage earlier this month when British Prime Minister David Cameron launched a global review of the crisis. “If we fail to act, we are looking at an almost unthinkable scenario where antibiotics no longer work and we are cast back into the dark ages of medicine where treatable infections and injuries will kill once again,” Mr Cameron noted... Realising the role of in vitro diagnostics in tackling antibiotic resistance, ... a side-event at the WHO’s World Health Assembly was hosted “The Fight Against Antimicrobial Resistance: Are Diagnostics Winning?” The event identified existing gaps in tackling AMR while highlighting the role of diagnostics.
Source : medtechviews.eu
|
|
Twitter
Copy link
Link copied!
|
Natera Receives CE Marking for Software | GenomeWeb Daily News | Sequencing | GenomeWeb
Natera today announced that its cloud-based software has received CE marking, allowing the company to market the product in the European Union and other countries that accept the designation. The software supports multiple applications, including Natera's Panorama non-invasive prenatal test, and delivers the company's analytical services to its laboratory customers ...
Source : genomeweb.com
|
|
Twitter
Copy link
Link copied!
|
Diaxonhit annonce la première commercialisation européenne du test AlloMap réalisé dans le laboratoire de référence de CareDx pour un patient allemand. La société et son partenaire américain, CareDx, font progresser la diffusion d'AlloMap hors des Etats-Unis avec un premier résultat de test rendu pour un patient de Munich.
|
|
Twitter
Copy link
Link copied!
|
A major software upgrade of an informatics solution centrally manages in vitro diagnostics analyzers and operators at point-of-care.
|
|
Twitter
Copy link
Link copied!
|
Roche renforce sa suprématie dans le cancer du sein
Le groupe acquiert la biotech Seragon pour 1,7 milliard de dollars.
L'opération valide sa stratégie d'acquisitions ciblées... Depuis le début de l'année, il a ainsi procédé à deux acquisitions pour sa branche Diagnostics. Après avoir renoncé en 2013 à racheter la société de séquençage Illumina, faute d'avoir pu s'entendre sur le prix, il a finalement repris début juin, pour 125 millions de dollars Genia Technologies, une société californienne dotée d'une plate-forme de séquençage utilisant les nanotechnologies.
Source : lesechos.fr
|
|
Twitter
Copy link
Link copied!
|
Bruker Corporation MALDI Biotyper(TM) Receives Clearance As A Medical Device From (CFDA)
Bruker Corporation today announced that it has received clearance from the China Food and Drug Administration (CFDA) to market and sell its IVD MALDI Biotyper System as a medical device in China for the identification of microorganisms isolated from human specimens.
Source : devicespace.com
|
|
Twitter
Copy link
Link copied!
|
Roche to Develop Assay as CDx for Ferring's Infertility Treatment | GenomeWeb Daily News | Clinical Genomics | GenomeWeb
Roche will develop an existing assay as a companion diagnostic for Ferring Pharmaceuticals' potential infertility treatment under a deal announced today. Roche will qualify, validate, document, and seek regulatory approval for its test, the Elecsys AMH assay, for use in combination with Ferring's human cell line-derived recombinant follicle-stimulating hormone, a gonadotrophin in phase III development. The Elecsys AMH assay evaluates anti-Müllerian hormone levels, a measure of a woman's ovarian reserve and her response to infertility treatment with gonadotrophin...
Source : genomeweb.com
|
|
Twitter
Copy link
Link copied!
|
Nicox Inc, la filiale américaine de Nicox, lance aux Etats-Unis le portefeuille RetnaGene™ de tests génétiques de Sequenom Laboratories en accès élargi.
|
|
Twitter
Copy link
Link copied!
|
Le groupe allemand Merck KGaA vient de signer un accord de collaboration avec Sysmex Inostics, une société de diagnostic moléculaire, pour l’élaboration et la commercialisation d’un test sanguin du biomarqueur RAS pour les patients atteints de...
|
|
Twitter
Copy link
Link copied!
|
FDA approves Qiagen's artus CMV RGQ MDx kit - Medical Devices Business Review
Qiagen has announced that its artus CMV RGQ MDx Kit for human cytomegalovirus (CMV) has been approved by the US Food and Drug Administration (FDA) under a full premarket approval (PMA).
The test is the only FDA-approved PCR-based assay optimized for low- to mid-throughput testing of CMV. With a turn-around time of approximately three hours, the assay provides faster results than other PMA approved tests.
Source : invitrodiagnostics.medicaldevices-business-review.com
|
|
Twitter
Copy link
Link copied!
|
RightBio Metrics Introduces New FDA Cleared Point-Of-Care Devices To Provide Safer, Cleaner And More Accurate Gastric pH Readings
PHOENIX, June 11, 2014 /PRNewswire/ -- RightBio Metrics, an emerging leader in advanced fluid measurement technologies, today announces the
Source : devicespace.com
|
|
Twitter
Copy link
Link copied!
|
|
Facebook
